The prolyl isomerase Pin1 orchestrates p53 acetylation and dissociation from the apoptosis inhibitor iASPP

Nature Structural and Molecular Biology

Volumn 14, Issue 10, 2007, Pages 912-920

  Mantovani, Fiamma ^a   Tocco, Francesca ^a   Girardini, Javier ^a   Smith, Paul ^b   Gasco, Milena ^c   Lu, Xin ^d   Crook, Tim ^b   Sal, Giannino Del ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c S CROCE E CARLE HOSPITAL   (Italy)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; APOPTOSIS INHIBITOR; ENZYME; PROLINE; PROLYL ISOMERASE PIN 1; PROTEIN P300; PROTEIN P53; SERINE; UNCLASSIFIED DRUG;

ACETYLATION; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DISSOCIATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY;

ACETYLATION; APOPTOSIS; CELL LINE, TUMOR; CHROMATIN; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASMS; P300-CBP TRANSCRIPTION FACTORS; PEPTIDYLPROLYL ISOMERASE; PHOSPHORYLATION; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34948830225     PISSN: 15459993     EISSN: 15459985     Source Type: Journal    
DOI: 10.1038/nsmb1306     Document Type: Article

References (53)

1. Appella, E. & Anderson, C.W. Post-translational modifications and activation of p53 by genotoxic stresses. Eur. J. Biochem. 268, 2764-2772 (2001).
2. Lavin, M.F. & Gueven, N. The complexity of p53 stabilization and activation. Cell Death Differ. 13, 941-950 (2006).
3. Gu, W. & Roeder, R.G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90, 595-606 (1997).
4. Luo, J. et al. Acetylation of p53 augments its site-specific DNA binding both in vitro and in vivo. Proc. Natl. Acad. Sci. USA 101, 2259-2264 (2004).
5. Knights, C.D. et al. Distinct p53 acetylation cassettes differentially influence gene-expression patterns and cell fate. J. Cell Biol. 173, 533-544 (2006).
6. Tang, Y., Luo, J., Zhang, W. & Gu, W. Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. Mol. Cell 24, 827-839 (2006).
7. Sykes, S.M. et al. Acetylation of the p53 DNA-binding domain regulates apoptosis induction. Mol. Cell 24, 841-851 (2006).
8. Ceskova, P., Chichger, H., Wallace, M., Vojtesek, B. & Hupp, T.R. On the mechanism of sequence-specific DNA-dependent acetylation of p53: the acetylation motif is exposed upon DNA binding. J. Mol. Biol. 357, 442-456 (2006).
9. Yaffe, M.B. et al. Sequence-specific and phosphorylation-dependent proline isomerization: a potential mitotic regulatory mechanism. Science 278, 1957-1960 (1997).
10. Yeh, E.S. & Means, A.R. PIN1, the cell cycle and cancer. Nat. Rev. Cancer 7, 381-388 (2007).
11. Bulavin, D.V. et al. Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation. EMBO J. 18, 6845-6854 (1999).
12. Buschmann, T. et al. Jun NH2-terminal kinase phosphorylation of p53 on Thr-81 is important for p53 stabilization and transcriptional activities in response to stress. Mol. Cell. Biol. 21, 2743-2754 (2001).
13. Hofmann, T.G. et al. Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2. Nat. Cell Biol. 4, 1-10 (2002).
14. D'Orazi, G. et al. Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat. Cell Biol. 4, 11-19 (2002).
15. Radhakrishnan, S.K. & Gartel, A.L. CDK9 phosphorylates p53 on serine residues 33, 315 and 392. Cell Cycle 5, 519-521 (2006).
16. Wang, Y. & Prives, C. Increased and altered DNA binding of human p53 by S and G2/M but not G1 cyclin-dependent kinases. Nature 376, 88-91 (1995).
17. Zacchi, P. et al. The prolyl isomerase Pin1 reveals a mechanism to control p53 functions after genotoxic insults. Nature 419, 853-857 (2002).
18. Zheng, H. et al. The prolyl isomerase Pin1 is a regulator of p53 in genotoxic response. Nature 419, 849-853 (2002).
19. Wulf, G.M., Liou, Y.C., Ryo, A., Lee, S.W. & Lu, K.P. Role of Pin1 in the regulation of p53 stability and p21 transactivation, and cell cycle checkpoints in response to DNA damage. J. Biol. Chem. 277, 47976-47979 (2002).
20. Berger, M., Stahl, N., Del Sal, G. & Haupt, Y. Mutations in proline 82 of p53 impair its activation by Pin1 and Chk2 in response to DNA damage. Mol. Cell. Biol. 25, 5380-5388 (2005).
21. Walker, K.K. & Levine, A.J. Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc. Natl. Acad. Sci. USA 93, 15335-15340 (1996).
22. Berger, M., Vogt Sionov, R., Levine, A.J. & Haupt, Y. A role for the polyproline domain of p53 in its regulation by Mdm2. J. Biol. Chem. 276, 3785-3790 (2001).
23. Dornan, D., Shimizu, H., Burch, L., Smith, A.J. & Hupp, T.R. The proline repeat domain of p53 binds directly to the transcriptional coactivator p300 and allosterically controls DNA-dependent acetylation of p53. Mol. Cell. Biol. 23, 8846-8861 (2003).
24. Venot, C. et al. The requirement for the p53 proline-rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression. EMBO J. 17, 4668-4679 (1998).
25. Zhu, J., Jiang, J., Zhou, W., Zhu, K. & Chen, X. Differential regulation of cellular target genes by p53 devoid of the PXXP motifs with impaired apoptotic activity. Oncogene 18, 2149-2155 (1999).
26. Toledo, F. et al. A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network. Cancer Cell 9, 273-285 (2006).
27. Chipuk, J.E. et al. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 303, 1010-1014 (2004).
28. Bergamaschi, D. et al. iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human. Nat. Genet. 33, 162-167 (2003).
29. Bergamaschi, D. et al. iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nat. Genet. 38, 1133-1141 (2006).
30. Matlashewski, G.J. et al. Primary structure polymorphism at amino acid residue 72 of human p53. Mol. Cell. Biol. 7, 961-963 (1987).
31. Thomas, M. et al. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol. Cell. Biol. 19, 1092-1100 (1999).
32. Sullivan, A. et al. Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene 23, 3328-3337 (2004).
33. Vassilev, L.T. et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844-848 (2004).
34. Mantovani, F. et al. Pin1 links the activities of c-Abl and p300 in regulating p73 function. Mol. Cell 14, 625-636 (2004).
35. Zhao, Y. et al. Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1). Mol. Cell. Biol. 26, 2782-2790 (2006).
36. Barlev, N.A. et al. Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol. Cell 8, 1243-1254 (2001).
37. Zhou, X.Z. et al. Pin1-dependent prolyl isomerization regulates dephosphorylation of cdc25 and tau proteins. Mol. Cell 6, 873-883 (2000).
38. Ard, P.G. et al. Transcriptional regulation of the mdm2 oncogene by p53 requires TRRAP acetyltransferase complexes. Mol. Cell. Biol. 22, 5650-5661 (2002).
39. Uchida, T. et al. Pin1 and Par14 peptidyl prolyl isomerase inhibitors block cell proliferation. Chem. Biol. 10, 15-24 (2003).
40. Kern, S.E. et al. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256, 827-830 (1992).
41. Dornan, D., Shimizu, H., Perkins, N.D. & Hupp, T.R. DNA-dependent acetylation of p53 by the transcription coactivator p300. J. Biol. Chem. 278, 13431-13441 (2003).
42. Bao, L. et al. Prevalent overexpression of prolyl isomerase Pin1 in human cancers. Am. J. Pathol. 164, 1727-1737 (2004).
43. Dornan, D. & Hupp, T.R. Inhibition of p53-dependent transcription by BOX-I phosphopeptide mimetics that bind to p300. EMBO Rep. 2, 139-144 (2001).
44. Sun, X.F. et al. A novel p53 germline alteration identified in a late onset breast cancer kindred. Oncogene 13, 407-411 (1996).
45. Wulf, G., Finn, G., Suizu, F. & Lu, K.P. Phosphorylation-specific prolyl isomerization: is there an underlying theme? Nat. Cell Biol. 7, 435-441 (2005).
46. Xu, Y.X., Hirose, Y., Zhou, X.Z., Lu, K.P. & Manley, J.L. Pin1 modulates the structure and function of human RNA polymerase II. Genes Dev. 17, 2765-2776 (2003).
47. Oda, K. et al. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 102, 849-862 (2000).
48. Mayo, L.D. et al. Phosphorylation of human p53 at serine 46 determines promoter selection and whether apoptosis is attenuated or amplified. J. Biol. Chem. 280, 25953-25959 (2005).
49. Samuels-Lev, Y. et al. ASPP proteins specifically stimulate the apoptotic function of p53. Mol. Cell 8, 781-794 (2001).
50. Geng, Y. et al. Cyclin E ablation in the mouse. Cell 114, 431-443 (2003).
51. Monte, M. et al. MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. Proc. Natl. Acad. Sci. USA 103, 11160-11165 (2006).
52. Kaeser, M.D. & Iggo, R.D. Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo. Proc. Natl. Acad. Sci. USA 99, 95-100 (2002).
53. -ΔΔC(T) method. Methods 25, 402-408 (2001).